---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-297146"
form_type: "8-K"
ticker: null
cik: "0001445499"
company_name: "IMPEL PHARMACEUTICALS INC"
filed_at: "2023-12-18T23:59:59+00:00"
generated_at: "2026-06-07T11:15:05.006428+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Impel Pharmaceuticals receives Nasdaq delisting; stock to move to OTC

## Summary
- Delisting due to failure to meet $50M MVLS and $15M MVPHS continued listing rules.
- Trading suspended at opening of business on December 18, 2023.
- Common stock expected to begin trading on the over-the-counter (OTC) market.
- No assurances that OTC trading will commence or be maintained given risks.

## SEC filing metadata
- accession: 0001193125-23-297146
- form_type: 8-K
- cik: 0001445499
- company_name: IMPEL PHARMACEUTICALS INC
- filed_at: 2023-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445499/000119312523297146/0001193125-23-297146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445499/000119312523297146/d623942d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-297146
- JSON: https://secwatch.observer/filing/0001193125-23-297146.json
- Plain text: https://secwatch.observer/filing/0001193125-23-297146.txt

## Key facts
- Listing & Compliance Notices
  IMPEL PHARMACEUTICALS INC received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(C), 5450(b)(2)(A)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: market value
  - Rules: 5450(b)(2)(C), 5450(b)(2)(A)
  source text: April 5, 2023, and that, for the for the 30-business day period ended April 5, 2023, the Company had not met the $50 million minimum market value of listed securities required to maintain continued listing as set forth in Nasdaq Marketplace Rule 5450(b)(2)(A) (the “ MVLS Rule ” and together with the MVPHS Rule, the “ Rules ”). As provided in the Nasdaq rules, the Company had 180 calendar days, or until October 9, 2023, to regain compliance. The Company did not regain compliance with such applicable Rules prior to October 9, 2023, and on October 16, 2023, the Company requested a hearing to rema
  evidence_url: https://www.sec.gov/Archives/edgar/data/1445499/000119312523297146/0001193125-23-297146-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.